Create

Sign in to ReadmeX

or

How we handle your data: Privacy Policy

ReadmeX

Your AI reading companion

What would you like to catch up on?

Pick a briefing, or ask your own question.

Your community and people briefings stay personal to you.

Story

Insilico Medicine reports 2026 first-half profitability and AI pipeline progress

AI summary

Insilico Medicine announced profitability in the first half of 2026, according to a 36Kr report. The report says 35 pipeline assets developed with its generative-AI platform, Pharma.AI, reached preclinical candidate compound status, while disclosed business-development cooperation involving its AI platform and pipeline totaled US$11 billion. In the interview, co-CEO Ren Feng said 70%–80% of the company’s code is written by AI and that AI now has substantial weight in drug-development decisions. He also said automated laboratories still require manual validation and calibration before experiments can be run, and that current technology is insufficient for a fully autonomous research loop.

In-depth insight

The interview provides first-hand detail on AI’s growing role in drug-development decisions and its potential to reduce time, labor and trial-and-error costs. It also identifies limits to fully autonomous laboratory research and the unresolved challenge of finding viable commercial applications for AI in pharmaceuticals.

文|胡香赟

编辑|海若镜

2026年,51岁的任峰身边,开始出现越来越多30岁出头的年轻同行。

任峰是英矽智能(03696.HK)的联席首席执行官。今年上半年,英矽智能正式宣布盈利,依托生成式AI平台Pharma.AI开发的35个管线资产进入PCC(临床前候选化合物),基于AI技术平台和管线的BD合作披露金额达到110亿美元,位居国内AI制药类企业之首。

任峰所处的制药行业,原本最为看重产业积淀、研发经验,可以说有些“论资排辈”的意思。但如今,AI正悄然改写这套运行多年的规则。凭借大语言模型的能力,年轻的博士生们尝试将传统的经验科学变为工程问题,也因此在而立的年纪,便能以创业者的身份走到台前,收获不菲融资与高估值。

他们和“任峰们”之间的代际差极其鲜明。

#Insilico Medicine#Pharma.AI#Science MMAI Gym#PandaOmics#Google Cloud#Tencent Health#Eli Lilly#Isomorphic Labs#Chai Discovery

Original · 15 min readRead the original
Group chat

No comments yet. Start the conversation.